LYEL
Lyell Immunopharma, Inc.NASDAQHealthcare$21.21+2.26%ClosedMarket Cap: $494.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.49
P/S
14042.53
EV/EBITDA
-2.53
DCF Value
$0.88
FCF Yield
-35.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-6558.3%
Operating Margin
-566038.9%
Net Margin
-762355.6%
ROE
-90.5%
ROA
-80.7%
ROIC
-70.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $6.0K | -39850.0% | $-62.0M | $-140.7M | $-6.62 | — |
| FY 2025 | $36.0K | -31952.8% | $-203.8M | $-274.4M | $-16.06 | — |
| Q3 2025 | $15.0K | 100.0% | $-37.3M | $-38.8M | $-2.13 | — |
| Q2 2025 | $8.0K | 100.0% | $-47.1M | $-42.7M | $-2.89 | — |
| Q1 2025 | $7.0K | 100.0% | $-57.4M | $-52.2M | $-0.18 | — |
| Q4 2024 | $11.0K | 100.0% | $-201.1M | $-191.9M | $-0.72 | — |
| FY 2024 | $61.0K | 100.0% | $-358.8M | $-343.0M | $-1.31 | — |
| Q3 2024 | $34.0K | 100.0% | $-50.5M | $-44.6M | $-0.17 | — |
| Q2 2024 | $13.0K | 100.0% | $-51.5M | $-45.8M | $-0.18 | — |
| Q1 2024 | $3.0K | 100.0% | $-55.6M | $-60.7M | $-0.24 | — |
| Q4 2023 | $13.0K | -38800.0% | $-59.8M | $-52.9M | $-0.21 | — |
| FY 2023 | $130.0K | 100.0% | $-247.0M | $-234.6M | $-0.93 | — |